VanEck Biotech ETF
Price through Oct 1 · Flows through Sep 30. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN · NET +$7M OVER THIS RANGE
Money keeps arriving — +$3M of net inflows over the past month, about 0.5% of the fund's asset base, while the price has returned +26.1% so far this year. At 0.35% a year it is not the cheapest way in — AVIE has a reported fee of 0.25%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | AMGNAMGEN | 15.79% | $407.27 | -3.4% | ||
| 2 | GILDGILEAD SCIENCES | 13.19% | $147.50 | -1.0% | ||
| 3 | VRTXVERTEX PHARMACEUTICALS | 8.22% | $506.74 | -3.1% | ||
| 4 | REGNREGENERON PHARMACEUTICALS | 6.50% | $734.81 | -3.1% | ||
| 5 | MRNAMODERNA | 6.07% | $188.94 | -1.9% | ||
| 6 | NTRANATERA | 5.34% | $408.47 | -1.2% | ||
| 7 | ARGXARGENX SE | 4.59% | $936.00 | -2.4% | ||
| 8 | IQVIQVIA HOLDINGS | 4.47% | $260.72 | -3.0% | ||
| 9 | RVMDREVOLUTION MEDICINES | 4.22% | $205.89 | +0.3% | ||
| 10 | ILMNILLUMINA | 4.05% | $265.72 | -2.9% | ||
| 11 | GHGUARDANT HEALTH | 3.01% | $174.75 | -2.0% | ||
| 12 | ONCBeiGene | 2.76% | $358.77 | -2.0% | ||
| 13 | BIIBBIOGEN | 2.73% | $222.82 | -1.4% | ||
| 14 | ALNYALNYLAM PHARMACEUTICALS | 2.70% | $231.18 | -6.3% | ||
| 15 | UTHRUNITED THERAPEUTICS | 2.24% | $571.38 | +5.4% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 26| 1 week | -2.7% |
| 1 month | -0.3% |
| 3 months | +16.8% |
| 6 months | +30.5% |
| YTD | +26.1% |
| 1 year | +38.7% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$2M |
| 1 month | +$3M |
| 3 months | +$12M |
| YTD | +$5M |
| 1 year | −$23M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 15.8% of the book; the top ten carry 72%. Spread across 25+ names, it behaves like roughly 14 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $35M | $34M |
| TEM TEMPUS AI INC | $4M | $5M |
| NTRA NATERA | $3M | $6M |
| AMGN AMGEN | $3M | $4M |
| UTHR UNITED THERAPEUTICS | $2M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat BBH on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -32bp on fee · 85× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -32bp on fee · 37× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.9B | +$497M | -31bp on fee · 67× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$575M | -31bp on fee · 48× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 38× the assets · +$412M in over the month | Head-to-head |